rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

TScan Therapeutics, Inc.

TCRX · Nasdaq

Health CareBiotechnologyNot moving yet

TCRX stood above a rising 150-day average in 1 of the last 52 weekly readings, and has been out of that trend for the last 51 weeks. It is 73.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 51
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$146K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
55 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 1 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders55+0 on the quarter
New · exited6 · 6
Reported value$32.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Lynx1 Capital Management LPunchanged · filed 12 Aug 20268,019,148$7.9M00.0%
BVF INCunchanged · filed 14 Aug 20265,564,290$5.5M00.0%
BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 20262,784,792$2.7M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,158,831$2.1M+4,575+0.2%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20261,949,604$1.9M+740,595+61.3%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20261,326,799$1.3M-37,984−2.8%
Deer Management Co. LLCunchanged · filed 14 Aug 20261,245,504$1.2M00.0%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20261,163,611$1.1M-296,674−20.3%
JACOBS LEVY EQUITY MANAGEMENT, INCadded · filed 14 Aug 20261,049,806$1.0M+241,450+29.9%
CITADEL ADVISORS LLCadded · filed 14 Aug 20261,009,107$989K+690,696+216.9%
31 Mar 2023 – 30 Jun 2026
275481Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Gavin MacBeath Company insiderChief Executive Officer · last 1 Oct 20262 · 0
Zoran Zdraveski Company insiderOfficer · last 1 Oct 20261 · 1
667, L.p. Company insiderDirector · last 20 May 20263 · 0
BAKER BROS. ADVISORS LP Company insiderDirector · last 20 May 20260 · 0
Barbara Klencke Company insiderDirector · last 20 May 20264 · 0
Gabriela Gruia Company insiderDirector · last 20 May 20260 · 0
Garry A. Nicholson Company insiderDirector · last 20 May 20260 · 0
Katina Dorton Company insiderDirector · last 20 May 20260 · 0
Keith Woods Company insiderDirector · last 20 May 20260 · 0
Chrystal Louis Company insiderChief Medical Officer · last 20 Jan 20260 · 0
Jason Amello Company insiderChief Financial Officer · last 20 Jan 20260 · 0
Leiden Dworak Company insiderOfficer · last 20 Jan 20260 · 0

Same industry

MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
XNCR XencorLeading+44%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-64.6%
Debt to equityFY 2025 · to 31 Dec 20250.26×
Interest coverFY 2025 · to 31 Dec 2025-49.05×
Cash and equivalentsFY 2025 · to 31 Dec 2025$152.4M
Free cash flowFY 2025 · to 31 Dec 2025−$139.7M

Analyst forecasts

No analyst forecasts yet.